IN2013CH01199A - - Google Patents

Download PDF

Info

Publication number
IN2013CH01199A
IN2013CH01199A IN1199CH2013A IN2013CH01199A IN 2013CH01199 A IN2013CH01199 A IN 2013CH01199A IN 1199CH2013 A IN1199CH2013 A IN 1199CH2013A IN 2013CH01199 A IN2013CH01199 A IN 2013CH01199A
Authority
IN
India
Prior art keywords
formula
compounds
useful
preparation
pharmaceutically acceptable
Prior art date
Application number
Other languages
English (en)
Inventor
Ramakrishna Nirogi
Anil Karbhari Shinde
Venkateswarlu Jasti
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA2907620A priority Critical patent/CA2907620C/fr
Priority to NZ712369A priority patent/NZ712369A/en
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Priority to PCT/IN2013/000639 priority patent/WO2014147636A1/fr
Priority to IN1199CH2013 priority patent/IN2013CH01199A/en
Priority to BR112015024060A priority patent/BR112015024060A2/pt
Priority to MX2015012350A priority patent/MX364929B/es
Priority to AP2015008742A priority patent/AP2015008742A0/xx
Priority to AU2013382944A priority patent/AU2013382944B2/en
Priority to EA201591844A priority patent/EA029365B1/ru
Priority to US14/777,925 priority patent/US9790211B2/en
Priority to EP13811624.9A priority patent/EP2976337B1/fr
Priority to CN201380074877.9A priority patent/CN105164119B/zh
Priority to JP2016504852A priority patent/JP6185650B2/ja
Priority to ES13811624.9T priority patent/ES2674993T3/es
Priority to KR1020157030158A priority patent/KR101815307B1/ko
Priority to SG11201507763RA priority patent/SG11201507763RA/en
Priority to DK13811624.9T priority patent/DK2976337T3/en
Publication of IN2013CH01199A publication Critical patent/IN2013CH01199A/en
Priority to ZA2015/06804A priority patent/ZA201506804B/en
Priority to HK16105434.5A priority patent/HK1217483A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
IN1199CH2013 2013-03-20 2013-10-18 IN2013CH01199A (fr)

Priority Applications (19)

Application Number Priority Date Filing Date Title
EP13811624.9A EP2976337B1 (fr) 2013-03-20 2013-10-18 Dérivés de 5-amino-quinoline-8-carboxamide en tant qu'agonistes du récepteur 5-ht4
US14/777,925 US9790211B2 (en) 2013-03-20 2013-10-18 5-amino-quinoline-8-carboxamide derivatives as 5-HT4 receptor agonists
CN201380074877.9A CN105164119B (zh) 2013-03-20 2013-10-18 作为5‑ht4受体激动剂的5‑氨基‑喹啉‑8‑甲酰胺衍生物
NZ712369A NZ712369A (en) 2013-03-20 2013-10-18 5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists
BR112015024060A BR112015024060A2 (pt) 2013-03-20 2013-10-18 composto, composição farmacêutica, método para o tratamento de doenças e uso de um composto
MX2015012350A MX364929B (es) 2013-03-20 2013-10-18 Derivados de la 5-amino-quinolina-8-carboxamida como agonistas del receptor 5-ht4.
AP2015008742A AP2015008742A0 (en) 2013-03-20 2013-10-18 5-amino quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists
AU2013382944A AU2013382944B2 (en) 2013-03-20 2013-10-18 5-Amino-quinoline-8-carboxamide derivatives as 5-HT4 receptor agonists
EA201591844A EA029365B1 (ru) 2013-03-20 2013-10-18 5-амино-хинолин-8-карбоксамидные производные в качестве агонистов 5-htрецептора
CA2907620A CA2907620C (fr) 2013-03-20 2013-10-18 Derives 5-amino-quinoline-8-carboxamides en tant qu'agonistes du recepteur 5-ht4
IN1199CH2013 IN2013CH01199A (fr) 2013-03-20 2013-10-18
PCT/IN2013/000639 WO2014147636A1 (fr) 2013-03-20 2013-10-18 Dérivés 5-amino-quinoline-8-carboxamides en tant qu'agonistes du récepteur 5-ht4
JP2016504852A JP6185650B2 (ja) 2013-03-20 2013-10-18 ５−ｈｔ４受容体アゴニストとしての５−アミノ−キノリン−８−カルボキサミド誘導体
ES13811624.9T ES2674993T3 (es) 2013-03-20 2013-10-18 Derivados de 5-amino-quinolina-8-carboxamida como agonistas del receptor 5-HT4
KR1020157030158A KR101815307B1 (ko) 2013-03-20 2013-10-18 5-ht4 수용체 효능제로서 5-아미노-퀴놀린-8-카르복사미드 유도체
SG11201507763RA SG11201507763RA (en) 2013-03-20 2013-10-18 5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists
DK13811624.9T DK2976337T3 (en) 2013-03-20 2013-10-18 5-amino-quinoline-8-carboxamide derivatives as 5-HT4 receptor agonists
ZA2015/06804A ZA201506804B (en) 2013-03-20 2015-09-14 5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists
HK16105434.5A HK1217483A1 (zh) 2013-03-20 2016-05-12 作爲 受體激動劑的 -氨基-喹啉- -甲酰胺衍生物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1199CH2013 IN2013CH01199A (fr) 2013-03-20 2013-10-18

Publications (1)

Publication Number Publication Date
IN2013CH01199A true IN2013CH01199A (fr) 2015-08-14

Family

ID=54325095

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1199CH2013 IN2013CH01199A (fr) 2013-03-20 2013-10-18

Country Status (19)

Country Link
US (1) US9790211B2 (fr)
EP (1) EP2976337B1 (fr)
JP (1) JP6185650B2 (fr)
KR (1) KR101815307B1 (fr)
CN (1) CN105164119B (fr)
AP (1) AP2015008742A0 (fr)
AU (1) AU2013382944B2 (fr)
BR (1) BR112015024060A2 (fr)
CA (1) CA2907620C (fr)
DK (1) DK2976337T3 (fr)
EA (1) EA029365B1 (fr)
ES (1) ES2674993T3 (fr)
HK (1) HK1217483A1 (fr)
IN (1) IN2013CH01199A (fr)
MX (1) MX364929B (fr)
NZ (1) NZ712369A (fr)
SG (1) SG11201507763RA (fr)
WO (1) WO2014147636A1 (fr)
ZA (1) ZA201506804B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016217461B2 (en) * 2015-02-13 2018-07-05 Suven Life Sciences Limited Amide compounds as 5-HT4 receptor agonists
CN109444301A (zh) * 2018-12-18 2019-03-08 江苏省中医院 一种测定血浆中普芦卡必利浓度的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2146930A1 (fr) * 1992-10-13 1994-04-28 Francis David King Esters ou amides heterocycliques, utilises comme antagonistes du recepteur 5-ht4
KR950704328A (ko) 1992-11-05 1995-11-17 데이비드 로버츠 5-HT₄ 수용체 길항제로서의 피페리딘 유도체(Piperidine Derivatives as 5-HT₄ Receptor Antagonists)
FR2756564B1 (fr) * 1996-12-04 2004-05-14 Synthelabo Derives d'acide quinoleine-8-carboxylique, leur preparation et leur application en therapeutique
WO2001095903A1 (fr) * 2000-06-15 2001-12-20 Respiratorius Ab Antagonistes du recepteur 5-ht3 destines au traitement de troubles englobant la constriction des voies aeriennes
WO2005003122A1 (fr) * 2003-06-19 2005-01-13 Janssen Pharmaceutica N.V. 4-(aminomethyl)-piperidine benzamides antagonistes des recepteurs 5ht4
JP4704353B2 (ja) 2003-11-24 2011-06-15 ファイザー株式会社 ５−ｈｔ４受容体アゴニスト活性を有するキノリンカルボン酸化合物
CA2551171C (fr) * 2003-12-23 2012-07-10 Bio-Medisinsk Innovasjon As Modulateurs de recepteurs peripheriques 5-ht
WO2005092882A1 (fr) * 2004-03-01 2005-10-06 Pfizer Japan, Inc. Derives de 4-amino-5-halogeno-benzamide utiles comme agonistes du recepteur 5-ht4 dans le traitement des troubles gastro-intestinaux, du systeme nerveux central, neurologiques et cardio-vasculaires
ES2523459T3 (es) 2005-02-25 2014-11-26 Raqualia Pharma Inc Derivados de benzisoxazol
EP1910340B1 (fr) 2005-07-22 2009-11-18 Pfizer, Inc. Derives d'indazolecarboxamides en tant qu'agonistes des recepteurs 5ht4
GB0525661D0 (en) * 2005-12-16 2006-01-25 Glaxo Group Ltd Novel compounds
EP2533780B1 (fr) * 2010-02-12 2017-08-23 AskAt Inc. Agonistes du récepteur 5-ht4 pour le traitement de la démence
IN2012DN06631A (fr) 2010-02-16 2015-10-23 Pfizer

Also Published As

Publication number Publication date
KR101815307B1 (ko) 2018-01-04
MX364929B (es) 2019-05-14
WO2014147636A8 (fr) 2014-12-04
CN105164119B (zh) 2017-12-08
CN105164119A (zh) 2015-12-16
ES2674993T3 (es) 2018-07-05
US9790211B2 (en) 2017-10-17
MX2015012350A (es) 2016-05-09
JP2016516089A (ja) 2016-06-02
AU2013382944B2 (en) 2016-08-04
SG11201507763RA (en) 2015-10-29
AP2015008742A0 (en) 2015-09-30
EA029365B1 (ru) 2018-03-30
EP2976337A1 (fr) 2016-01-27
HK1217483A1 (zh) 2017-01-13
EP2976337B1 (fr) 2018-05-02
AU2013382944A1 (en) 2015-10-08
CA2907620C (fr) 2018-03-13
CA2907620A1 (fr) 2014-09-25
ZA201506804B (en) 2016-07-27
DK2976337T3 (en) 2018-07-16
KR20160004274A (ko) 2016-01-12
JP6185650B2 (ja) 2017-08-23
WO2014147636A1 (fr) 2014-09-25
NZ712369A (en) 2016-11-25
US20160280694A1 (en) 2016-09-29
EA201591844A1 (ru) 2016-08-31
BR112015024060A2 (pt) 2017-07-18

Similar Documents

Publication Publication Date Title
PH12019501321B1 (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders
PH12018502125A1 (en) Bipyrazole derivatives as jak inhibitors
IN2015DN01156A (fr)
MX2016011632A (es) Derivados de azaspiro como antagonistas de trpm8.
MD20150071A2 (ro) Compuşi azabenzimidazolici ca inhibitori ai PDE4 izoenzimelor pentru tratamentul tulburărilor SNC şi altor afecţiuni
WO2014155300A3 (fr) Dérivés pyrimidine aminée substitués en tant qu'inhibiteurs de tak-1
EA201590183A1 (ru) Производные азаиндола, выступающие в качестве ингибиторов pi3k
MX2016005759A (es) Derivados de piridina sustituidos, utiles como inhibidores de glucogeno sintasa cinasa 3 (gsk-3).
TN2015000120A1 (en) Oxazolidin-2-one-pyrimidine derivatives
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
PH12017500089A1 (en) Aldosterone synthase inhibitors
EA201790830A1 (ru) Ингибиторы альдостеронсинтазы
MY176521A (en) Pyrrole-substituted indolone derivative, preparation method therefor, composition comprising the same and use thereof
MX2016009621A (es) Derivados de fur0-3-carboxamida y metodos de uso.
IN2013MU03862A (fr)
MX2016008898A (es) Antagonistas selectivos de nr2b.
EA201691252A1 (ru) Соединения индазола в качестве агонистов 5-ht-рецептора
MX2013013436A (es) Derivados de indol sustituidos para el tratamiento de transtornos inmunologicos.
IN2013CH01199A (fr)
MX2015000064A (es) Compuestos de acrilamida como ligandos receptores de histamina h3.
PH12015502703A1 (en) Pharmaceutical compositions
IN2013MU03838A (fr)
MX2015012393A (es) Derivados oxindol con un sustituyente oxetano y uso de los mismos para tratar enfermedades relacionadas con la vasopresina.